BNT-113 is a mrna vaccine commercialized by BioNTech, with a leading Phase II program in Cervical Cancer. According to Globaldata, it is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of BNT-113’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for BNT-113 is expected to reach an annual total of $18 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
BNT-113 is under development for the treatment of human papillomavirus (HPV) positive head and neck squamous cell carcinoma (HNSCC), cervical cancer and penile cancer. The drug candidate is administered through intradermal and intravenous route. It is an mRNA therapeutic encoding human papillomavirus serotype 16 oncoproteins E6 and E7. It is developed based on FixVac technology (fixed combination of shared antigens).
BioNTech is a biotechnology company that develops immunotherapies for cancer and infectious diseases. It is investigating mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate, head and neck, ovarian, pancreatic and triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, influenza and covid-19. BioNTech utilizes FixVac and iNeST technology platforms to discover and develop cancer immunotherapies targeting antigens and neoantigens. It works in partnership with Genentech Inc, Eli Lilly and Co, Genmab AS, and other biopharmaceutical companies to develop its pipeline products. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.
The company reported revenues of (Euro) EUR18,976.7 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of EUR482.3 million in FY2020. The operating profit of the company was EUR15,283.8 million in FY2021, compared to an operating loss of EUR82.4 million in FY2020. In FY2021, the company recorded a net margin of 54.2%, compared to a net margin of 3.2% in FY2020. The company reported revenues of EUR3,461.2 million for the third quarter ended September 2022, an increase of 8.3% over the previous quarter.
For a complete picture of BNT-113’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.